The dysregulation of miR-7 is a hallmark of several major pathologies:
: Restoring miR-7 levels through "mimics" is being explored as an adjuvant therapy to sensitize cancer cells to chemotherapy and overcome multidrug resistance.
: Its expression levels in peripheral blood or tissues can serve as a biomarker for cancer prognosis or disease staging. Mirna.7z
: It generally acts as a tumor suppressor . Its downregulation is linked to increased proliferation and metastasis in glioblastoma, lung, breast, and colorectal cancers by failing to inhibit oncogenic pathways like EGFR/PI3K/Akt .
: Recent studies highlight its role in regulating immune responses, including T-cell activation and neuroinflammation. Clinical Potential Due to its broad regulatory reach, miR-7 is a target for: The dysregulation of miR-7 is a hallmark of
miR-7 is preferentially expressed in neuroendocrine tissues, specifically the and pancreas .
: Its levels are controlled post-transcriptionally by "sponges" like circular RNA ciRS-7 (also known as CDR1as), which contains over 70 binding sites for miR-7 and can effectively quench its activity. Role in Pathophysiology Its downregulation is linked to increased proliferation and
: It regulates the development of the pituitary gland, optic nervous system, and cerebral cortex by targeting factors like PAX6 , which is essential for eye and brain organogenesis.